Abstract
This report was prepared to promote the safety results of intravitreal cord-blood platelet-rich plasma (CB-PRP) use for dry-age-related macular degeneration (dry-AMD) as possible regenerative therapy. We believe that the safety data is important to convey while waiting for the results of possible efficacy. A dissemination of safety information in the use of CB-PRP for intravitreal use could help us with future collaborations and be able to study its real potential that only large numbers can provide. We believe in the regenerative power of CB-PRP. Moreover, funding for this research is completely absent. We trust that the Editor may consider it.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
